Want to see ECOR full AI Analyst Report?
ECOR Stock Chart & Stats
$6.50
$0.45(2.64%)
At close: 4:00 PM EST
$6.50
$0.45(2.64%)
Day’s Range― - ―
52-Week Range$4.16 - $10.50
Previous CloseN/A
Volume24.66K
Average Volume (3M)33.66K
Market Cap
$48.78M
Enterprise Value$54.64
Total Cash (Recent Filing)$8.83M
Total Debt (Recent Filing)$9.48M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 12, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding8,295,707
10 Day Avg. Volume29,982
30 Day Avg. Volume33,656
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.62Price Target Upside155.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$41.92M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And High Gross MarginsSustained revenue scaling combined with mid‑80s gross margins indicate strong unit economics and pricing power in nVNS devices. High gross margins provide structural room to absorb SG&A and fund R&D, improving prospects that revenue growth will translate into operating leverage and eventual profitability.
Reaffirmed Guidance And Record QuarterManagement’s reaffirmation after a record quarter gives durable topline visibility and suggests execution across channels. Clear mid‑teens to 30% growth targets support multi‑period planning, capacity allocation, and longer‑term commercialization investments rather than one‑off cyclical gains.
VA Channel Traction And Addressable PenetrationStrong and growing VA reimbursement traction provides a durable revenue base tied to federal payor adoption. Early low penetration implies a multi‑year runway within a defined addressable market; federal channel success also raises barriers to entry and encourages predictable, recurring device and therapy purchases.
Bears Say
Persistent Negative Free Cash FlowConsistent negative operating and free cash flow means the business requires ongoing external financing to sustain growth. This structural cash burn increases dilution or refinancing risk, constrains discretionary investment, and makes execution vulnerable if capital markets tighten or funding costs rise.
Negative Shareholders' Equity And Shrinking AssetsA shift to negative equity and declining asset base materially weakens financial flexibility. This structural balance‑sheet deterioration increases refinancing, covenant and dilution risk, reduces borrowing capacity, and constrains strategic options like partnerships or M&A without corrective capital measures.
Ongoing Operating Losses And Elevated SG&ADespite margin expansion, persistent operating losses and high SG&A create a lasting profitability gap. If fixed commercial costs stay elevated while revenue growth slows or is uneven across product lines, the company may struggle to reach sustainable breakeven without further cost reductions or stronger top‑line momentum.
Electrocore News
ECOR FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was $4.16 and its highest was $10.49 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is $48.78M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on May 06, 2026. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.022.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.42.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 8,295,707 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -5.856%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in ECOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.62 (155.64% Upside)
$16.62 (155.64% Upside)
Insider Transactions
Sold Shares
Worth $563.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.72%
12-Months-Change
Fundamentals
Return on Equity
836.32%
Trailing 12-Months
Asset Growth
-3.48%
Trailing 12-Months
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
ECOR Stock 12 Month Forecast
Average Price Target
$16.62
▲(155.64% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
13.80% Insiders
3.15% Mutual Funds
<0.01% Other Institutional Investors
80.31% Public Companies and
Individual Investors